Goosebumps: for me, the FDA corruption issue drives the BO vs go it alone issue. I fully agree with ohm's premise that the shareholders will be far better served by staying independent and growing revenue to the moon. But that strategy assumes (and requires) a US FDA that will approve LL in a reasonably timely manner for the myriad of indications that will generate those revenues. Most of that enormous revenue would be generated from the US, and approvals from the US FDA may even prove necessary to gain approvals abroad, a scenario now playing out.

Having observed the incomprehensible LL roadblocks that the FDA has constructed so far for HIV and Covid, I have serious doubts if the FDA, either through corruption or mindless bureaucratic obstinacy, will approve LL for any indication over the next several years. If that is what we are actually dealing with (the $64 dollar question so to speak), then I would reluctantly take a BO in 2021 (priced at a reasonable discount to future LL revenue) over a share price below $3 in 2024.